CA2063529A1 - Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same - Google Patents
Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the sameInfo
- Publication number
- CA2063529A1 CA2063529A1 CA002063529A CA2063529A CA2063529A1 CA 2063529 A1 CA2063529 A1 CA 2063529A1 CA 002063529 A CA002063529 A CA 002063529A CA 2063529 A CA2063529 A CA 2063529A CA 2063529 A1 CA2063529 A1 CA 2063529A1
- Authority
- CA
- Canada
- Prior art keywords
- booster
- liquid
- medicament
- ultrasound
- microbubbles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 44
- 201000010099 disease Diseases 0.000 title claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 49
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 15
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 5
- 229910001882 dioxygen Inorganic materials 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 16
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 16
- 229960005356 urokinase Drugs 0.000 description 16
- 208000007536 Thrombosis Diseases 0.000 description 10
- 238000001647 drug administration Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 230000020764 fibrinolysis Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
Abstract
ABSTRACT
The present invention is directed to a booster comprising plenty of gaseous microbubbles in a liquid, e.g. about 4 x 107 cells/ml of gaseous microbubbles having a diameter of 0.1 to 100 µm in a 3 to 5% human serum albumin solution. The invention is further directed to a pharmaceutical liquid composition comprising the booster as set forth above and a medicament. The medicament is used in combination with ultrasonic vibrations for the treatment of various diseases.
The therapeutic effects of the medicament are enhanced by the application of ultrasound in the presence of the booster.
The present invention is directed to a booster comprising plenty of gaseous microbubbles in a liquid, e.g. about 4 x 107 cells/ml of gaseous microbubbles having a diameter of 0.1 to 100 µm in a 3 to 5% human serum albumin solution. The invention is further directed to a pharmaceutical liquid composition comprising the booster as set forth above and a medicament. The medicament is used in combination with ultrasonic vibrations for the treatment of various diseases.
The therapeutic effects of the medicament are enhanced by the application of ultrasound in the presence of the booster.
Description
Booster for Ultrasound Treatment of Diseases and A
Pharmaceutical Liquld Composition Containing the Same This invention relates to a booster useful fox enhancing the effects of ultrasound in the treatment of various diseases, a pharmaceutical liquid composition containing the booster and a medicament which shows enhanced diffusion and penetration of the medicament into the body by applying ultrasound. More particularly, it relates to a booster useful for treatment of various diseases by applying ultrasound, said booster comprising plenty of gaseous microbubbles in a liquid, a pharmaceutical liquid composition comprising plenty of gaseous microbubbles and a medicament in a liquid, and the use thereof in the treatment of various diseases while applying ultrasound.
It is known that various diseases are remedied with the aid of ultrasonic vibration. For example, it is described in Japanese Patent First Publica~ion (Kokai) No. 115591/1977, etc. that percutaneous absorption of a medicament is enhanced by applying ultrasonic vibration. Japanese Patent First 20 Publication (Kokai) No. 180275/1990 discloses a drug-injecting device which is effective on the diffusion and penetration of the drug by applying ultrasonic vibration during the step of injecting a drug into a human body via a catheter or a drug-injecting tube. U.S. Patent Nos. 4,953,565 and 5,007,438 also disclose the technique of percutaneous absorption of medicaments with the aid of ultrasonic vibration. It is also reported that a tumour can be remedied by concentratedly applying ultrasound from outside the ~ody.
In order to enhance the therapeutic effects with ultrasound, it is often necessary to apply a higher energy of ultrasonic vibration. However, if the energy is too hiyh burning can occur or the generation of unnecessary heat at a portion other than the desired portion can also occur. on the other hand, when the energy of the ultrasonic vibration is lowered to eliminate such disadvantages, the ultrasound is less effective at the desired portion.
Pharmaceutical Liquld Composition Containing the Same This invention relates to a booster useful fox enhancing the effects of ultrasound in the treatment of various diseases, a pharmaceutical liquid composition containing the booster and a medicament which shows enhanced diffusion and penetration of the medicament into the body by applying ultrasound. More particularly, it relates to a booster useful for treatment of various diseases by applying ultrasound, said booster comprising plenty of gaseous microbubbles in a liquid, a pharmaceutical liquid composition comprising plenty of gaseous microbubbles and a medicament in a liquid, and the use thereof in the treatment of various diseases while applying ultrasound.
It is known that various diseases are remedied with the aid of ultrasonic vibration. For example, it is described in Japanese Patent First Publica~ion (Kokai) No. 115591/1977, etc. that percutaneous absorption of a medicament is enhanced by applying ultrasonic vibration. Japanese Patent First 20 Publication (Kokai) No. 180275/1990 discloses a drug-injecting device which is effective on the diffusion and penetration of the drug by applying ultrasonic vibration during the step of injecting a drug into a human body via a catheter or a drug-injecting tube. U.S. Patent Nos. 4,953,565 and 5,007,438 also disclose the technique of percutaneous absorption of medicaments with the aid of ultrasonic vibration. It is also reported that a tumour can be remedied by concentratedly applying ultrasound from outside the ~ody.
In order to enhance the therapeutic effects with ultrasound, it is often necessary to apply a higher energy of ultrasonic vibration. However, if the energy is too hiyh burning can occur or the generation of unnecessary heat at a portion other than the desired portion can also occur. on the other hand, when the energy of the ultrasonic vibration is lowered to eliminate such disadvantages, the ultrasound is less effective at the desired portion.
The present inventors have studied intensively to enhance the effects of ultrasound with a lower ultrasonic vibration energy and have found that a booster comprising plenty of gaseous microbubbles in a liquid is useful for the desired enhancement of the effects of ultrasound.
An object of the invention is to provide a booster useful for enhancing the effects of ultrasound which comprises plenty of gaseous microbubbles in a liquid. Another object of the invention is to provide a pharmaceutical liquid c~mposition containing the booster and a medicament which is useful for the treatment of various diseases together with the application of ultrasound. A further object of the invention is to provide a method for enhancing the effects by the application of ultrasound in the treatment of various diseases which comprises injecting the booster or the pharmaceutical liquid composition as set forth above into the portion to be remedied while applying ultrasound thereto. These and other objects and advantages of the invention will be apparent to those skilled in the art from the following description.
In drawings that illustrate preferred embodiments of the present invention:
Fig. 1 shows a schematic view of one of the microbubbles contained in the booster of the invention.
Fig. 2 shows a schematic sectional view of one embodiment of a drug administration de~ice used for injecting, pouring, applying or circulating the booster or the pharmaceutical liquid composition of the invention.
Fig. 3. shows a schematic sectional view of one embodiment of a drug administration device used for percutaneous injection of the booster or the pharmaceutical liquid composition of the invention.
Fig. 4 and Fig 5 are graphs showing fibrinolysis by application of ultrasound with or without the booster of the invention.
The booster of the invention comprises a liquid containing plenty of gaseous microbubbles having a diameter of O.1 to 100 ~m. The microbubbles are formed by entrapping ,~
microspheres of a gas into a liquid. The booster con~ains, for example, about 4 x 107 of the microbubbles per one milliliter of a liquid. The microbubbles are made of various gases, for example, air, oxygen gas, carbon dioxide gas, inert gases (e.g. xenon, krypt~n, argon, neon, helium, etc.), preferably air and oxygen gas. The liquid includes any liquid which can form microbubbles, for example, human serum albumin (e.g. 3 to 5~ human serum albumin), a physiological saline solution, a 5% aqueous glucose solution, an aqueous lo indocyanine green solution, autoblood, an aqueous solution of maglumine diatriazoate (= renografin), and any other X-ray contrast medium.
The booster can be prepared by a known method, for example, by agitating the liquid as mentioned above while blowing a gas as mentioned above into the liquid, or alternatively exposing the liquid to ultrasound with a sonicator under a gaseous atmosphere, whereby vibration is imparted to the liquid to form microbubbles of the gas.
The pharmaceutical liquid composition of the invention comprises plenty of gaseous microbubbles and a medicament in a liquid. The gaseous microbubbles and liquid are the same as mentioned above. The medicament includes any known medicaments effective for the desired therapy which can be absorbed percutaneously, for example, anti-thrombosis agents (e.g. urokinase, tissue plasminogen activator, etc.), hormones (e.g. insulin, etc.), theophylline, lidocaine, antibiotics, antineoplastic agents which are sensitive to ultrasound (e.g.
doxorubicin (= adriamycin), cytarabine (= Ara-C), etc.), and the like. The medicament can be contained in a therapeutically effective amount as usually used. The pharmaceutical liquid composition can be prepared by mixing a medicament with a booster comprising plenty of gaseous microbubbles in a liquid. The mixing ratio may vary depending on the desirQd amount and type of medicament and the type of 35 liquid, but is usually in a range of l : 100 to lO0 : 1 by weight ta medicament/a booster).
.~
s.
According to the invention, th~ therapeutic effects of ultrasound are boosted by the presence o~ the booster of the present invention. Particularly, when a pharmaceutical liquid composition containing the booster and a medicament is poured or injected into a body by usual parenteral routes, e.g.
intravenously, percutaneously or intramuscularly, while applying thereto ultrasonic vibration, the therapeutic effects of the medicament are significantly enhanced. When ultrasound vibration from an ultrasonic element is applied to the liquid containing the booster and medicament, cavitation occurs in the liquid composition, and the medicament is diffused and penetrated into the desired portion of the patient with the aid of vibration induced by the cavitation. The cavitation occurs when the level of vibration energy is higher than a certain threshold value. When the ultrasound is applied to the liquid composition of the invention, the threshold value of the vibration energy is lowered due to the presence of plenty of gaseous microbubbles. That is, the gaseous microbubbles act as a nucleus of cavitation and thereby the cavitation occurs more easily. According to the invention, the desired ultrasonic energy necessary for the desired diffusion and penetration of a medicament is achieved by even less ultrasonic vibration energy.
The desired ultrasound vibration is applied using conventional ultrasonic devices which can supply a ultrasonic signal of 20 KHz to several MHz.
With reference to the accompanying drawing, the invention is illustrated in more detail.
Fig. 1 shows a schematic view of one of the gaseous microbubbles contained in the booster of the invention, wherein the gaseous microbubble has a diameter of 0.1 to 100 ~m and is composed of a shell of human serum albumin (1) and a gas (2) entrapped within the microbubble. The microbubbles are contained in a liquid (3) such as 5% human serum albumin solution in an amount of, for example, above 4 x 107 cells/ml.
''. ' ~
The booster is mixed with a medicament to give a pharmaceutical liquid composition. The pharmaceutical liquid composition is directly administered to the diseased part with an appropriate device, for example, with a drug administration device (4) as shown in Fig. 2. The drug administration device (4) comprises a base tube (5) to which the pharmaceutical li~uid composition is supplied, and an end tube (6) which is to be inserted into the tissue of the patient and through which the pharmaceutical liquid composition is poured or injected into the diseased part. The end tube (6) is provided with a ultrasonic element (7) (e.g. a cylindrical ceramic oscillator, etc.). The ultrasonic ~lement (7) is supplied with an ultrasonic signal of 20 KHz to several MHz from a ultrasonic oscillation circuit (8) via a conductor (9a), connectors (lOa) and (lOb) provided on the side of the base tube (5), a part of the base tube (5) and a conductor (9b) provided within the end tube (6).
The application or injection of a-medicament is carried out in the form of a pharmaceutical liquid composition which is prepared by previously mixing the medicament with the booster-comprising plenty of gaseous microbubbles in a liquid, wherein the medicament and the booster are mixed in a ratio of 1 : 100 to 100 : 1 by weight. The pharmaceutical liquid composition is poured into the base tube (5) from the supply opening (11) provided on the tip of the base tube (5), passes through a flow path (12) within the base tube (5~ and a flow path (13) within the end tube (6) and is then administered to the diseased part or a portion close thereto of the patient via a pouring opening (14) provided at the bottom of the end tube (6).
When the pharmaceutical liquid composition is administered into the diseased part or a portion close thereto through the pouring opening (14), ultrasonic energy generated from the ultrasonic element (7) is given to the liquid composition, by which cavitation occurs owing to ~he ultrasonic energy. Microbubbles are formed at the occurrence of cavitation and when the microbubbles are decomposed, energy is generated, by which diffusion and penetration of the medicament is promoted. Since the pharmaceutical liquid composition contains plenty of gaseous microbubbles, the microbubbles act as a nucleus for the cavitation, by which the cavitation occurs more easily, in other words, the threshold value of occurrence of cavitation lowers. Accordingly, it is possible to generate the cavitation with less energy than in the case where no booster is used.
When ultrasonic vibration is applied to a liquid, if the liquid contains any material being able to become a nucleus, the cavitation occurs generally at a lower threshold value of energy, but it has been found that the cavitation occurs most easily where the liquid contains gaseous microbubbles having a diameter of 0.1 to 100 ~m.
The drug administration device (4) as shown in Fig. 2 can be used, for example, for administering a pharmaceutical liquid composition into a blood vessel. For instance, in the treatment of coronary thrombosis, a pharmaceutical liquid composition comprising a booster of the invention and a urokinase is injected into the part of thrombosis or a close portion thereof with the drug administration device (4) where the tip of the end tube (6) is inserted into the portion close to the thrombosis with the application of ultrasound, by which the thrombolytic effects of the medicament are significantly increased and further the blood flow is recovered within a shorter period of time in comparison with the administration of the medicament without the booster. The drug administration device (4) may also be used to remove hematoma in the brain.
For example, a pharmaceutical liquid composition comprising a booster of the invention and a thrombolytic agent (e.g. urokinase) is administered to a portion of the hematoma with the drug administration device (4) with the application of ultrasound, by which the hematoma is easily lysed In another embodiment of the invention, the pharma-ceutical liquid composition can be administered percutaneously with a drug administration device (15) as shown in Fig. 3.
' .
.
In the drug administration device (15) suitable for percutaneous administr~tion of a medicament, a layer of a medicament (17) is provided below an ultrasonic element (16) (e.g. a disc shaped ceramic oscillator, etc.), under which there is permeability laminated thereto an adhesive layer (18) having a medicament, the whole of which is covered with a plastic cover (19). The ultrasonic element (16) is supplied with an ultrasonic signal from an ultrasonic oscillation circuit provided outside via a connector (20) as in the dru~
administration device (4) as shown in Fig. 2.
In the device (15) of Fig. 3, a pharmaceutical liquid composition comprising a mixture of a booster and a medicament is contained in the medicament layer (17). When this device (15) is used, it is adhered onto the skin with the adhesive layer (18) facing the skin, and then an ultrasonic signal is supplied to the ultrasonic element (16), by which an ultrasonic vibration from the ultrasonic element (16) is given to both the medicament layer (17) and the skin. Thereby, the medicament contained in the medicament layer (17) is passed through the skin and penetrates into the tissue to be treated.
In this embodiment, since gaseous microbubbles are contained in the medicament layer (17), cavitation occurs easily within the medicament layer (17) by application of u]trasound, and hence even lower ultrasonic vibration energy is supplied from the ultrasonic element (16), the diffusion and penetration of the medicament can effectively be done to result in rapid absorption of the medicament.
The booster of the invention may also be used alone without mixing with a medicament in ultrasound therapies. For example, in the treatment of tumours by heating the diseased part of the tissue with ultrasound, that is, by concentratedly applying ultrasonic vibration outside the patient, a booster comprising plenty of gaseous microbubbles in a liquid of the invention is first injected into a blood vessel or to a portion close to the diseased part before application of ultrasound, by which the effect of heating with ultrasound is enhanced and thereby the therapeutic effects are significantly .
:. .
`
improved. In this embodiment, cavitation also occurs by the ultrasonic vibration more easily because use is made of a liquid containing gaseous microbubbles, and hence, even with less ultrasonic vibration energy supplied from the ultrasonic element, sufficient ultrasonic energy is obtained for the therapy and thereby undesirable burns and unnecessary heating at other portions can be avoided.
In the treatment of tumours, it is, of course, more effective to use it together with a chemotherapeutic agent suitable for the treatment of the tumours, by which the effects of the chemotherapeutic agent are more enhanced, where the diffusion and penetration of the medicament are improved owing to the booster.
The substance, e.g. human serum albumin, in the booster of the invention is easily metabolized within the patient and is excreted, and hence, it is not harmful to the patient.
Besides, the amount of gas trapped within the microbubbles is extremely small and is easily dissolved in the blood.
Accordingly, the booster of the invention has no safety problems.
The preparation of the booster and pharmaceutical liquid composition of the invention and effects thereof are illustrated by the following Examples and Experiment, but it should not be constxued to be limited thereto.
Example 1 Preparation of a booster:
A 5% human serum albumin (8 ml) in a 10 ml-volume syringe was exposed to ultrasound with a sonicator (frequency, 20 KHz) by which vibration was given to the human serum albumin and plenty of microbubbles of air were formed in the human serum albumin to give a booster comprising a human serum albumin containing plenty of microbubbles of air~
Exam~le 2 Preparation of a pharmaceutical liquid composition:
The 5% human serum albumin containlng plenty of ,~
microbubbles of air prepared in Example 1 was mixed with urokinase (concentration 1200 IU/ml) to give the desired pharmaceutical liquid composition.
Experiment 1. Forming artificial thromaosis An artificial thromaosis was form~d by Chandler's method.
slood (1 ml) collected from healthy humans (two persons) was placed in a flexible tube (inside diameter 3 mm, length 265 mm) and thereto was added calcium chloride. Then, the tube was made into a loop like shape, which was rotated at 12 r.p.m. for 20 minutes to give an artificial thrombosis model.
2. Ultrasonic catheter A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness l mm) was inserted into the tip of a catheter (diameter 2 mm), and an oscillating element was connected to an oscillator provided outside with a fine connector passing through the catheter~ A fine tube for pouring a test solution was provided at an opening opposite to the opening of the catheter end.
An object of the invention is to provide a booster useful for enhancing the effects of ultrasound which comprises plenty of gaseous microbubbles in a liquid. Another object of the invention is to provide a pharmaceutical liquid c~mposition containing the booster and a medicament which is useful for the treatment of various diseases together with the application of ultrasound. A further object of the invention is to provide a method for enhancing the effects by the application of ultrasound in the treatment of various diseases which comprises injecting the booster or the pharmaceutical liquid composition as set forth above into the portion to be remedied while applying ultrasound thereto. These and other objects and advantages of the invention will be apparent to those skilled in the art from the following description.
In drawings that illustrate preferred embodiments of the present invention:
Fig. 1 shows a schematic view of one of the microbubbles contained in the booster of the invention.
Fig. 2 shows a schematic sectional view of one embodiment of a drug administration de~ice used for injecting, pouring, applying or circulating the booster or the pharmaceutical liquid composition of the invention.
Fig. 3. shows a schematic sectional view of one embodiment of a drug administration device used for percutaneous injection of the booster or the pharmaceutical liquid composition of the invention.
Fig. 4 and Fig 5 are graphs showing fibrinolysis by application of ultrasound with or without the booster of the invention.
The booster of the invention comprises a liquid containing plenty of gaseous microbubbles having a diameter of O.1 to 100 ~m. The microbubbles are formed by entrapping ,~
microspheres of a gas into a liquid. The booster con~ains, for example, about 4 x 107 of the microbubbles per one milliliter of a liquid. The microbubbles are made of various gases, for example, air, oxygen gas, carbon dioxide gas, inert gases (e.g. xenon, krypt~n, argon, neon, helium, etc.), preferably air and oxygen gas. The liquid includes any liquid which can form microbubbles, for example, human serum albumin (e.g. 3 to 5~ human serum albumin), a physiological saline solution, a 5% aqueous glucose solution, an aqueous lo indocyanine green solution, autoblood, an aqueous solution of maglumine diatriazoate (= renografin), and any other X-ray contrast medium.
The booster can be prepared by a known method, for example, by agitating the liquid as mentioned above while blowing a gas as mentioned above into the liquid, or alternatively exposing the liquid to ultrasound with a sonicator under a gaseous atmosphere, whereby vibration is imparted to the liquid to form microbubbles of the gas.
The pharmaceutical liquid composition of the invention comprises plenty of gaseous microbubbles and a medicament in a liquid. The gaseous microbubbles and liquid are the same as mentioned above. The medicament includes any known medicaments effective for the desired therapy which can be absorbed percutaneously, for example, anti-thrombosis agents (e.g. urokinase, tissue plasminogen activator, etc.), hormones (e.g. insulin, etc.), theophylline, lidocaine, antibiotics, antineoplastic agents which are sensitive to ultrasound (e.g.
doxorubicin (= adriamycin), cytarabine (= Ara-C), etc.), and the like. The medicament can be contained in a therapeutically effective amount as usually used. The pharmaceutical liquid composition can be prepared by mixing a medicament with a booster comprising plenty of gaseous microbubbles in a liquid. The mixing ratio may vary depending on the desirQd amount and type of medicament and the type of 35 liquid, but is usually in a range of l : 100 to lO0 : 1 by weight ta medicament/a booster).
.~
s.
According to the invention, th~ therapeutic effects of ultrasound are boosted by the presence o~ the booster of the present invention. Particularly, when a pharmaceutical liquid composition containing the booster and a medicament is poured or injected into a body by usual parenteral routes, e.g.
intravenously, percutaneously or intramuscularly, while applying thereto ultrasonic vibration, the therapeutic effects of the medicament are significantly enhanced. When ultrasound vibration from an ultrasonic element is applied to the liquid containing the booster and medicament, cavitation occurs in the liquid composition, and the medicament is diffused and penetrated into the desired portion of the patient with the aid of vibration induced by the cavitation. The cavitation occurs when the level of vibration energy is higher than a certain threshold value. When the ultrasound is applied to the liquid composition of the invention, the threshold value of the vibration energy is lowered due to the presence of plenty of gaseous microbubbles. That is, the gaseous microbubbles act as a nucleus of cavitation and thereby the cavitation occurs more easily. According to the invention, the desired ultrasonic energy necessary for the desired diffusion and penetration of a medicament is achieved by even less ultrasonic vibration energy.
The desired ultrasound vibration is applied using conventional ultrasonic devices which can supply a ultrasonic signal of 20 KHz to several MHz.
With reference to the accompanying drawing, the invention is illustrated in more detail.
Fig. 1 shows a schematic view of one of the gaseous microbubbles contained in the booster of the invention, wherein the gaseous microbubble has a diameter of 0.1 to 100 ~m and is composed of a shell of human serum albumin (1) and a gas (2) entrapped within the microbubble. The microbubbles are contained in a liquid (3) such as 5% human serum albumin solution in an amount of, for example, above 4 x 107 cells/ml.
''. ' ~
The booster is mixed with a medicament to give a pharmaceutical liquid composition. The pharmaceutical liquid composition is directly administered to the diseased part with an appropriate device, for example, with a drug administration device (4) as shown in Fig. 2. The drug administration device (4) comprises a base tube (5) to which the pharmaceutical li~uid composition is supplied, and an end tube (6) which is to be inserted into the tissue of the patient and through which the pharmaceutical liquid composition is poured or injected into the diseased part. The end tube (6) is provided with a ultrasonic element (7) (e.g. a cylindrical ceramic oscillator, etc.). The ultrasonic ~lement (7) is supplied with an ultrasonic signal of 20 KHz to several MHz from a ultrasonic oscillation circuit (8) via a conductor (9a), connectors (lOa) and (lOb) provided on the side of the base tube (5), a part of the base tube (5) and a conductor (9b) provided within the end tube (6).
The application or injection of a-medicament is carried out in the form of a pharmaceutical liquid composition which is prepared by previously mixing the medicament with the booster-comprising plenty of gaseous microbubbles in a liquid, wherein the medicament and the booster are mixed in a ratio of 1 : 100 to 100 : 1 by weight. The pharmaceutical liquid composition is poured into the base tube (5) from the supply opening (11) provided on the tip of the base tube (5), passes through a flow path (12) within the base tube (5~ and a flow path (13) within the end tube (6) and is then administered to the diseased part or a portion close thereto of the patient via a pouring opening (14) provided at the bottom of the end tube (6).
When the pharmaceutical liquid composition is administered into the diseased part or a portion close thereto through the pouring opening (14), ultrasonic energy generated from the ultrasonic element (7) is given to the liquid composition, by which cavitation occurs owing to ~he ultrasonic energy. Microbubbles are formed at the occurrence of cavitation and when the microbubbles are decomposed, energy is generated, by which diffusion and penetration of the medicament is promoted. Since the pharmaceutical liquid composition contains plenty of gaseous microbubbles, the microbubbles act as a nucleus for the cavitation, by which the cavitation occurs more easily, in other words, the threshold value of occurrence of cavitation lowers. Accordingly, it is possible to generate the cavitation with less energy than in the case where no booster is used.
When ultrasonic vibration is applied to a liquid, if the liquid contains any material being able to become a nucleus, the cavitation occurs generally at a lower threshold value of energy, but it has been found that the cavitation occurs most easily where the liquid contains gaseous microbubbles having a diameter of 0.1 to 100 ~m.
The drug administration device (4) as shown in Fig. 2 can be used, for example, for administering a pharmaceutical liquid composition into a blood vessel. For instance, in the treatment of coronary thrombosis, a pharmaceutical liquid composition comprising a booster of the invention and a urokinase is injected into the part of thrombosis or a close portion thereof with the drug administration device (4) where the tip of the end tube (6) is inserted into the portion close to the thrombosis with the application of ultrasound, by which the thrombolytic effects of the medicament are significantly increased and further the blood flow is recovered within a shorter period of time in comparison with the administration of the medicament without the booster. The drug administration device (4) may also be used to remove hematoma in the brain.
For example, a pharmaceutical liquid composition comprising a booster of the invention and a thrombolytic agent (e.g. urokinase) is administered to a portion of the hematoma with the drug administration device (4) with the application of ultrasound, by which the hematoma is easily lysed In another embodiment of the invention, the pharma-ceutical liquid composition can be administered percutaneously with a drug administration device (15) as shown in Fig. 3.
' .
.
In the drug administration device (15) suitable for percutaneous administr~tion of a medicament, a layer of a medicament (17) is provided below an ultrasonic element (16) (e.g. a disc shaped ceramic oscillator, etc.), under which there is permeability laminated thereto an adhesive layer (18) having a medicament, the whole of which is covered with a plastic cover (19). The ultrasonic element (16) is supplied with an ultrasonic signal from an ultrasonic oscillation circuit provided outside via a connector (20) as in the dru~
administration device (4) as shown in Fig. 2.
In the device (15) of Fig. 3, a pharmaceutical liquid composition comprising a mixture of a booster and a medicament is contained in the medicament layer (17). When this device (15) is used, it is adhered onto the skin with the adhesive layer (18) facing the skin, and then an ultrasonic signal is supplied to the ultrasonic element (16), by which an ultrasonic vibration from the ultrasonic element (16) is given to both the medicament layer (17) and the skin. Thereby, the medicament contained in the medicament layer (17) is passed through the skin and penetrates into the tissue to be treated.
In this embodiment, since gaseous microbubbles are contained in the medicament layer (17), cavitation occurs easily within the medicament layer (17) by application of u]trasound, and hence even lower ultrasonic vibration energy is supplied from the ultrasonic element (16), the diffusion and penetration of the medicament can effectively be done to result in rapid absorption of the medicament.
The booster of the invention may also be used alone without mixing with a medicament in ultrasound therapies. For example, in the treatment of tumours by heating the diseased part of the tissue with ultrasound, that is, by concentratedly applying ultrasonic vibration outside the patient, a booster comprising plenty of gaseous microbubbles in a liquid of the invention is first injected into a blood vessel or to a portion close to the diseased part before application of ultrasound, by which the effect of heating with ultrasound is enhanced and thereby the therapeutic effects are significantly .
:. .
`
improved. In this embodiment, cavitation also occurs by the ultrasonic vibration more easily because use is made of a liquid containing gaseous microbubbles, and hence, even with less ultrasonic vibration energy supplied from the ultrasonic element, sufficient ultrasonic energy is obtained for the therapy and thereby undesirable burns and unnecessary heating at other portions can be avoided.
In the treatment of tumours, it is, of course, more effective to use it together with a chemotherapeutic agent suitable for the treatment of the tumours, by which the effects of the chemotherapeutic agent are more enhanced, where the diffusion and penetration of the medicament are improved owing to the booster.
The substance, e.g. human serum albumin, in the booster of the invention is easily metabolized within the patient and is excreted, and hence, it is not harmful to the patient.
Besides, the amount of gas trapped within the microbubbles is extremely small and is easily dissolved in the blood.
Accordingly, the booster of the invention has no safety problems.
The preparation of the booster and pharmaceutical liquid composition of the invention and effects thereof are illustrated by the following Examples and Experiment, but it should not be constxued to be limited thereto.
Example 1 Preparation of a booster:
A 5% human serum albumin (8 ml) in a 10 ml-volume syringe was exposed to ultrasound with a sonicator (frequency, 20 KHz) by which vibration was given to the human serum albumin and plenty of microbubbles of air were formed in the human serum albumin to give a booster comprising a human serum albumin containing plenty of microbubbles of air~
Exam~le 2 Preparation of a pharmaceutical liquid composition:
The 5% human serum albumin containlng plenty of ,~
microbubbles of air prepared in Example 1 was mixed with urokinase (concentration 1200 IU/ml) to give the desired pharmaceutical liquid composition.
Experiment 1. Forming artificial thromaosis An artificial thromaosis was form~d by Chandler's method.
slood (1 ml) collected from healthy humans (two persons) was placed in a flexible tube (inside diameter 3 mm, length 265 mm) and thereto was added calcium chloride. Then, the tube was made into a loop like shape, which was rotated at 12 r.p.m. for 20 minutes to give an artificial thrombosis model.
2. Ultrasonic catheter A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness l mm) was inserted into the tip of a catheter (diameter 2 mm), and an oscillating element was connected to an oscillator provided outside with a fine connector passing through the catheter~ A fine tube for pouring a test solution was provided at an opening opposite to the opening of the catheter end.
3. Test method The artificial thrombosis prepared above was added to a test tube together with blood, and the ultrasonic catheter was inserted into the test tube so that the end of the catheter was set close to the portion of the artificial thrombosis (at a distance of about 5 mm), and to the test tube a mixture of urokinase and a booster prepared in Example 1 was added at a rate of 1 ml per minute, wherein urokinase (concentration 1200 IU/ml) and the booster were mixed immediately before pouring at a mixing ratio of 1 : 1 by weight. The mixture was refluxed while keeping the volume of the test solution at a constant level by removing excess volume of the solution b~
suction. Ultrasound vibration (170 KHz) was exposed to the mixture using a pulse method (exposed for 2 seconds and stopped for 4 secands) for 2 minutes (total exposing time 40 seconds). After the exposure, the ultrason1c catheter was removed from the test tube, and the mixture was incubated at .
~. . . . . . .. .
370C for 5 to 120 minutes, washed with a physiological saline solution several times and dried overnight. ~hereafter, the dried mi~ture was weighed. As a control, the above was repeated using only a physiological saline solution.
suction. Ultrasound vibration (170 KHz) was exposed to the mixture using a pulse method (exposed for 2 seconds and stopped for 4 secands) for 2 minutes (total exposing time 40 seconds). After the exposure, the ultrason1c catheter was removed from the test tube, and the mixture was incubated at .
~. . . . . . .. .
370C for 5 to 120 minutes, washed with a physiological saline solution several times and dried overnight. ~hereafter, the dried mi~ture was weighed. As a control, the above was repeated using only a physiological saline solution.
4. Test results The rate of fibrinolysis was calculated by the following equation:
Weight of Weight of [thrombosis] - [thrombosis]
lO Fibrinolysis rate (%) = in control treated x 100 Weight of thrombosis in control The results are shown in the accompanying Figs. 4 and 5.
An average of two tests is shown.
Fig. 4 shows the results in the thrombosis prepared by using blood collected from one person, wherein the symbol -~-is the data obtained from the addition of urokinase alone without ultrasound exposure, -~- is the data obtained from the addition of urokinase alone with ultrasound exposure, and -~-is the data obtained from the addition of a mixture of urokinase and the booster with ultrasound exposure.
As is shown in Fig. 4, the time to achieve 20~
fibrinolysis was 45 minutes with urokinase alone without ultrasound exposure, 30 minutes with a combination of urokinase and ultrasound exposure, and only 10 minutes with a combination of a mixture of urokinase and a booster and ultrasound exposure. The fibrinolytic effects of urokinase ~both the rate of fibrinolysis and the fibrinolytic time) were significantly enhanced using a booster with the ultrasound application.
Fig. 5 shows the results in the thrombosis prepared using blood collected from another person and with ultrasound energy reduced by 15%, wherein the symbols are the same as in Fig. 4.
As is shown in Fig. 5, the fibrinolytic effects were significantly enhanced using a mixture of urokinase and the booster. That is, in the case using urokinase alone with ultrasound exposure, 50% fibrinolysis was achieved by ! .
`~ ' '' treatment for 60 minutes, but in the case using a mixture of urokinase and the booster with ultrasound exposure, it was reduced to one fourth, i.e. it was achieved by the treatment after only 15 minutes.
.
Weight of Weight of [thrombosis] - [thrombosis]
lO Fibrinolysis rate (%) = in control treated x 100 Weight of thrombosis in control The results are shown in the accompanying Figs. 4 and 5.
An average of two tests is shown.
Fig. 4 shows the results in the thrombosis prepared by using blood collected from one person, wherein the symbol -~-is the data obtained from the addition of urokinase alone without ultrasound exposure, -~- is the data obtained from the addition of urokinase alone with ultrasound exposure, and -~-is the data obtained from the addition of a mixture of urokinase and the booster with ultrasound exposure.
As is shown in Fig. 4, the time to achieve 20~
fibrinolysis was 45 minutes with urokinase alone without ultrasound exposure, 30 minutes with a combination of urokinase and ultrasound exposure, and only 10 minutes with a combination of a mixture of urokinase and a booster and ultrasound exposure. The fibrinolytic effects of urokinase ~both the rate of fibrinolysis and the fibrinolytic time) were significantly enhanced using a booster with the ultrasound application.
Fig. 5 shows the results in the thrombosis prepared using blood collected from another person and with ultrasound energy reduced by 15%, wherein the symbols are the same as in Fig. 4.
As is shown in Fig. 5, the fibrinolytic effects were significantly enhanced using a mixture of urokinase and the booster. That is, in the case using urokinase alone with ultrasound exposure, 50% fibrinolysis was achieved by ! .
`~ ' '' treatment for 60 minutes, but in the case using a mixture of urokinase and the booster with ultrasound exposure, it was reduced to one fourth, i.e. it was achieved by the treatment after only 15 minutes.
.
Claims (13)
1. A booster for enhancing effects of ultrasound in the treatment of diseases, said booster comprising plenty of gaseous microbubbles having a diameter of 0.1 to 100 µm in a liquid.
2. The booster according to claim 1, wherein the microbubbles are formed from air or oxygen gas in the liquid.
3. The booster according to claim 1, wherein the liquid is a 3 to 5% human serum albumin solution.
4. A pharmaceutical liquid composition for the treatment of diseases with application of ultrasound, said pharmaceutical liquid composition comprising plenty of gaseous microbubbles having a diameter of 0.1 to 100 µm and a medicament in a liquid.
5. The composition according to claim 4, wherein the microbubbles are formed from air or oxygen gas in the liquid.
6. The composition according to claim 4, wherein the liquid is a 3 to 5% human serum albumin solution.
7. The composition according to claim 4, wherein the medicament is a member selected from thrombolytic agents, hormones, antibiotics, and antineoplastic agents.
8. A method for enhancing the therapeutic effects of a medicament, which comprises administering a pharmaceutical liquid composition as set forth in claim 4 while applying ultrasound.
9. The method according to claim 8, wherein the liquid composition comprises about 4 x 107 cells/ml of gaseous microbubbles having a diameter of 0.1 to 100 µm and a medicament in the liquid.
10. The method according to claim 9, wherein the liquid is a 3 to 5% human serum albumin solution.
11. Use of a pharmaceutical liquid composition comprising plenty of gaseous microbubbles having a diameter of 0.1 to 100 µm and a medicament in a liquid in the treatment of diseases by applying ultrasound.
12. The use according to claim 11, wherein the microbubbles are formed from air or oxygen gas in the liquid.
13. The use according to claim 11, wherein the liquid is a 3 to 5% human serum albumin solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58970/1991 | 1991-03-22 | ||
JP5897091 | 1991-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2063529A1 true CA2063529A1 (en) | 1992-09-23 |
Family
ID=13099707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002063529A Abandoned CA2063529A1 (en) | 1991-03-22 | 1992-03-19 | Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same |
Country Status (5)
Country | Link |
---|---|
US (5) | US5315998A (en) |
EP (2) | EP0504881B2 (en) |
AT (1) | ATE146073T1 (en) |
CA (1) | CA2063529A1 (en) |
DE (1) | DE69215722T3 (en) |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
DE69215722T3 (en) * | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5713848A (en) * | 1993-05-19 | 1998-02-03 | Dubrul; Will R. | Vibrating catheter |
US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
EP0711179B2 (en) | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
DE59409568D1 (en) * | 1993-09-09 | 2000-11-30 | Schering Ag | ACTIVE SUBSTANCES AND GAS CONTAINING MICROPARTICLES |
DE4330958A1 (en) * | 1993-09-09 | 1995-03-16 | Schering Ag | Novel microparticles containing active compound, media containing these, their use for the ultrasonically controlled release of active compounds and process for the production thereof |
US5814599A (en) * | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
WO1996022111A1 (en) * | 1995-01-19 | 1996-07-25 | Sound Science Limited Partnership | Local delivery and monitoring of drugs |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US6210356B1 (en) * | 1998-08-05 | 2001-04-03 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6002961A (en) * | 1995-07-25 | 1999-12-14 | Massachusetts Institute Of Technology | Transdermal protein delivery using low-frequency sonophoresis |
US5947921A (en) * | 1995-12-18 | 1999-09-07 | Massachusetts Institute Of Technology | Chemical and physical enhancers and ultrasound for transdermal drug delivery |
US6041253A (en) * | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
US5735811A (en) | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
US5728062A (en) * | 1995-11-30 | 1998-03-17 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
US5725494A (en) | 1995-11-30 | 1998-03-10 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced intraluminal therapy |
WO1997029701A1 (en) * | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter based surgery |
ATE248511T1 (en) * | 1996-03-12 | 2003-09-15 | Univ Nebraska | COMPOSITION FOR TARGETED ADMINISTRATION OF A MEDICATION AND METHOD OF USE |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
AU736301B2 (en) | 1996-05-01 | 2001-07-26 | Imarx Therapeutics, Inc. | Methods for delivering compounds into a cell |
JP2002515786A (en) | 1996-06-28 | 2002-05-28 | ソントラ メディカル,エル.ピー. | Ultrasound enhancement of transdermal delivery |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
BE1010407A4 (en) | 1996-07-04 | 1998-07-07 | Undatim Ultrasonics | Method and installation of water treatment. |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US5846218A (en) * | 1996-09-05 | 1998-12-08 | Pharmasonics, Inc. | Balloon catheters having ultrasonically driven interface surfaces and methods for their use |
US6464660B2 (en) | 1996-09-05 | 2002-10-15 | Pharmasonics, Inc. | Balloon catheters having ultrasonically driven interface surfaces and methods for their use |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
ATE366588T1 (en) | 1996-09-11 | 2007-08-15 | Imarx Pharmaceutical Corp | METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR |
US6024717A (en) * | 1996-10-24 | 2000-02-15 | Vibrx, Inc. | Apparatus and method for sonically enhanced drug delivery |
US6221038B1 (en) | 1996-11-27 | 2001-04-24 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6723063B1 (en) | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
US6582392B1 (en) * | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US5931805A (en) * | 1997-06-02 | 1999-08-03 | Pharmasonics, Inc. | Catheters comprising bending transducers and methods for their use |
US6228046B1 (en) | 1997-06-02 | 2001-05-08 | Pharmasonics, Inc. | Catheters comprising a plurality of oscillators and methods for their use |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
EP1043949A2 (en) | 1997-12-31 | 2000-10-18 | Pharmasonics, Inc. | Methods and systems for the inhibition of vascular hyperplasia |
US8287483B2 (en) * | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
US20060015058A1 (en) * | 1998-01-08 | 2006-01-19 | Kellogg Scott C | Agents and methods for enhancement of transdermal transport |
US7066884B2 (en) | 1998-01-08 | 2006-06-27 | Sontra Medical, Inc. | System, method, and device for non-invasive body fluid sampling and analysis |
US7273458B2 (en) | 1998-01-12 | 2007-09-25 | Georgia Tech Research Corporation | Method of applying acoustic energy effective to alter transport or cell viability |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
JPH11244283A (en) * | 1998-03-05 | 1999-09-14 | Ge Yokogawa Medical Systems Ltd | Ultrasonic image pickup method and its device |
US6135976A (en) * | 1998-09-25 | 2000-10-24 | Ekos Corporation | Method, device and kit for performing gene therapy |
US20040171980A1 (en) * | 1998-12-18 | 2004-09-02 | Sontra Medical, Inc. | Method and apparatus for enhancement of transdermal transport |
US6361554B1 (en) | 1999-06-30 | 2002-03-26 | Pharmasonics, Inc. | Methods and apparatus for the subcutaneous delivery of acoustic vibrations |
US6387116B1 (en) | 1999-06-30 | 2002-05-14 | Pharmasonics, Inc. | Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts |
AU6636000A (en) * | 1999-08-13 | 2001-03-13 | Point Biomedical Corporation | Hollow microspheres with controlled fragility for medical use |
US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US6944493B2 (en) * | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6439236B1 (en) | 1999-10-25 | 2002-08-27 | The Board Of Regents Of The University Of Nebraska | Methods for inducing atrial and ventricular rhythms using ultrasound and microbubbles |
US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US20040158317A1 (en) * | 2000-07-18 | 2004-08-12 | Pharmasonics, Inc. | Coated stent with ultrasound therapy |
US6514221B2 (en) * | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001293112A1 (en) * | 2000-09-25 | 2002-04-02 | Advanced Medical Applications, Inc. | Ultrasonic method and device for wound treatment |
US6964647B1 (en) * | 2000-10-06 | 2005-11-15 | Ellaz Babaev | Nozzle for ultrasound wound treatment |
US6601581B1 (en) | 2000-11-01 | 2003-08-05 | Advanced Medical Applications, Inc. | Method and device for ultrasound drug delivery |
US6533803B2 (en) | 2000-12-22 | 2003-03-18 | Advanced Medical Applications, Inc. | Wound treatment method and device with combination of ultrasound and laser energy |
US6761729B2 (en) | 2000-12-22 | 2004-07-13 | Advanced Medicalapplications, Inc. | Wound treatment method and device with combination of ultrasound and laser energy |
US7914470B2 (en) * | 2001-01-12 | 2011-03-29 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
US8235919B2 (en) * | 2001-01-12 | 2012-08-07 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
US6569099B1 (en) | 2001-01-12 | 2003-05-27 | Eilaz Babaev | Ultrasonic method and device for wound treatment |
IL141123A0 (en) * | 2001-01-26 | 2002-02-10 | Iger Yoni | Method and apparatus for the delivery of substances to biological components |
US6960173B2 (en) * | 2001-01-30 | 2005-11-01 | Eilaz Babaev | Ultrasound wound treatment method and device using standing waves |
DE10108798A1 (en) * | 2001-02-19 | 2002-09-26 | Laser & Med Tech Gmbh | Method and device for ultrasound-supported transmembrane medication application in vivo |
US6623444B2 (en) | 2001-03-21 | 2003-09-23 | Advanced Medical Applications, Inc. | Ultrasonic catheter drug delivery method and device |
DE10119522A1 (en) * | 2001-04-20 | 2002-12-05 | Innovacell Biotechnologie Gmbh | Preparation and application of a suspension composition with an ultrasound contrast medium |
US6478754B1 (en) | 2001-04-23 | 2002-11-12 | Advanced Medical Applications, Inc. | Ultrasonic method and device for wound treatment |
US8123789B2 (en) * | 2002-04-29 | 2012-02-28 | Rohit Khanna | Central nervous system cooling catheter |
JP4426288B2 (en) * | 2001-07-10 | 2010-03-03 | ソノジーン,リミテッド ライアビリティー カンパニー | Enhanced transfection of liver DNA |
ATE520362T1 (en) | 2001-12-03 | 2011-09-15 | Ekos Corp | CATHETER WITH MULTIPLE ULTRASONIC EMITTING PARTS |
US7141044B2 (en) * | 2001-12-11 | 2006-11-28 | Ekos Corporation | Alternate site gene therapy |
AU2002357316A1 (en) | 2001-12-14 | 2003-06-30 | Ekos Corporation | Blood flow reestablishment determination |
IL148299A (en) * | 2002-02-21 | 2014-04-30 | Technion Res & Dev Foundation | Ultrasound cardiac stimulator |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
JP4243499B2 (en) * | 2002-06-11 | 2009-03-25 | 富士通株式会社 | Bonded substrate manufacturing apparatus and bonded substrate manufacturing method |
DE10393505D2 (en) * | 2002-07-22 | 2005-06-23 | Hans-Werner Bender | Sound applicator device for improving the treatment conditions |
US6921371B2 (en) * | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
EP1562642B1 (en) * | 2002-11-04 | 2007-01-10 | Ashland Inc. | Device and process for treating a liquid medium using ultrasound in preventing the growth of hyperproliferative or infected cells |
JP2004182728A (en) * | 2002-11-22 | 2004-07-02 | Katsuro Tachibana | Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue |
CA2545798A1 (en) * | 2003-02-19 | 2004-09-02 | Dermisonics, Inc. | Ultrasonically enhanced saline treatment for burn damaged skin |
WO2004097017A2 (en) | 2003-04-29 | 2004-11-11 | Avi Biopharma, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US7048863B2 (en) * | 2003-07-08 | 2006-05-23 | Ashland Licensing And Intellectual Property Llc | Device and process for treating cutting fluids using ultrasound |
WO2005056105A2 (en) * | 2003-12-11 | 2005-06-23 | Hans-Werner Bender | Device consisting of a sonic applicator and a carrier element |
US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
US9107590B2 (en) | 2004-01-29 | 2015-08-18 | Ekos Corporation | Method and apparatus for detecting vascular conditions with a catheter |
US7341569B2 (en) * | 2004-01-30 | 2008-03-11 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
JP2008504119A (en) | 2004-06-23 | 2008-02-14 | アシュランド・ライセンシング・アンド・インテレクチュアル・プロパティー・エルエルシー | Apparatus and method for treating liquids utilized in electrodeposition processes using ultrasound |
US20060094944A1 (en) * | 2004-10-28 | 2006-05-04 | Sontra Medical Corporation | System and method for analyte sampling and analysis with error correction |
EP1828059B1 (en) | 2004-11-17 | 2013-11-20 | Ashland Licensing and Intellectual Property LLC | Method for treating cooling fluids utilized in tire manufacturing |
WO2006063199A2 (en) | 2004-12-09 | 2006-06-15 | The Foundry, Inc. | Aortic valve repair |
CA2604380A1 (en) * | 2005-04-12 | 2006-10-19 | Ekos Corporation | Ultrasound catheter with cavitation promoting surface |
US7713218B2 (en) | 2005-06-23 | 2010-05-11 | Celleration, Inc. | Removable applicator nozzle for ultrasound wound therapy device |
US7785277B2 (en) * | 2005-06-23 | 2010-08-31 | Celleration, Inc. | Removable applicator nozzle for ultrasound wound therapy device |
US7717853B2 (en) * | 2005-06-24 | 2010-05-18 | Henry Nita | Methods and apparatus for intracranial ultrasound delivery |
US20110160621A1 (en) * | 2005-06-24 | 2011-06-30 | Henry Nita | Methods and apparatus for dissolving intracranial blood clots |
US9101949B2 (en) * | 2005-08-04 | 2015-08-11 | Eilaz Babaev | Ultrasonic atomization and/or seperation system |
US20070031611A1 (en) * | 2005-08-04 | 2007-02-08 | Babaev Eilaz P | Ultrasound medical stent coating method and device |
US7896539B2 (en) * | 2005-08-16 | 2011-03-01 | Bacoustics, Llc | Ultrasound apparatus and methods for mixing liquids and coating stents |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
CA2621535A1 (en) * | 2005-09-07 | 2007-03-15 | The Foundry, Inc. | Apparatus and method for disrupting subcutaneous structures |
US7967763B2 (en) * | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US10548659B2 (en) | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
US9358033B2 (en) | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
GB0518273D0 (en) * | 2005-09-08 | 2005-10-19 | Univ Dundee | Apparatus and method for sonoporation |
US8257338B2 (en) * | 2006-10-27 | 2012-09-04 | Artenga, Inc. | Medical microbubble generation |
US20080200864A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US9248317B2 (en) * | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US20080014627A1 (en) * | 2005-12-02 | 2008-01-17 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US20080197517A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US7885793B2 (en) | 2007-05-22 | 2011-02-08 | International Business Machines Corporation | Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution |
US20080200863A1 (en) * | 2005-12-02 | 2008-08-21 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US20080195036A1 (en) * | 2005-12-02 | 2008-08-14 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US7432069B2 (en) * | 2005-12-05 | 2008-10-07 | Sontra Medical Corporation | Biocompatible chemically crosslinked hydrogels for glucose sensing |
WO2007102933A2 (en) * | 2006-01-06 | 2007-09-13 | Imarx Therapeutics, Inc | Composition for ultrasound therapy and pharmaceutical liquid composition containing the same |
EP2015846A2 (en) | 2006-04-24 | 2009-01-21 | Ekos Corporation | Ultrasound therapy system |
US7431704B2 (en) * | 2006-06-07 | 2008-10-07 | Bacoustics, Llc | Apparatus and method for the treatment of tissue with ultrasound energy by direct contact |
US8562547B2 (en) | 2006-06-07 | 2013-10-22 | Eliaz Babaev | Method for debriding wounds |
US20080097316A1 (en) * | 2006-08-21 | 2008-04-24 | Leonid Malinin | Ultrasound catheter |
WO2008024923A2 (en) | 2006-08-25 | 2008-02-28 | Eilaz Babaev | Portable ultrasound device for the treatment of wounds |
US20080089848A1 (en) * | 2006-10-11 | 2008-04-17 | Dimauro Thomas | Intrathecal injection of microbubbles |
US8192363B2 (en) * | 2006-10-27 | 2012-06-05 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
US20080142616A1 (en) * | 2006-12-15 | 2008-06-19 | Bacoustics Llc | Method of Producing a Directed Spray |
WO2008079379A1 (en) * | 2006-12-22 | 2008-07-03 | Celleration, Inc. | Apparatus to prevent applicator re-use |
US8491521B2 (en) | 2007-01-04 | 2013-07-23 | Celleration, Inc. | Removable multi-channel applicator nozzle |
US20080214965A1 (en) * | 2007-01-04 | 2008-09-04 | Celleration, Inc. | Removable multi-channel applicator nozzle |
EP2111261B1 (en) | 2007-01-08 | 2015-04-15 | Ekos Corporation | Power parameters for ultrasonic catheter |
US10182833B2 (en) * | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
US8812071B2 (en) * | 2007-03-07 | 2014-08-19 | Echo Therapeutics, Inc. | Transdermal analyte monitoring systems and methods for analyte detection |
JP2010525881A (en) | 2007-04-27 | 2010-07-29 | エコー セラピューティクス, インコーポレイテッド | Skin permeation device for analyte detection or transdermal drug delivery |
EP2494932B1 (en) | 2007-06-22 | 2020-05-20 | Ekos Corporation | Apparatus for treatment of intracranial hemorrhages |
US7753285B2 (en) | 2007-07-13 | 2010-07-13 | Bacoustics, Llc | Echoing ultrasound atomization and/or mixing system |
US7780095B2 (en) | 2007-07-13 | 2010-08-24 | Bacoustics, Llc | Ultrasound pumping apparatus |
US20090093723A1 (en) * | 2007-10-05 | 2009-04-09 | Cabochon Aesthetics, Inc. | Ultrasound device including dispenser |
EP2209424A1 (en) * | 2007-10-09 | 2010-07-28 | Cabochon Aesthetics, Inc. | Ultrasound apparatus with treatment lens |
US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
US20090093738A1 (en) * | 2007-10-09 | 2009-04-09 | Cabochon Aesthetics, Inc. | Device and method for monitoring a treatment area |
CN100560157C (en) * | 2007-11-13 | 2009-11-18 | 重庆市生力医疗设备有限公司 | Ultrasonic medicine plaster |
US8262645B2 (en) * | 2007-11-21 | 2012-09-11 | Actuated Medical, Inc. | Devices for clearing blockages in in-situ artificial lumens |
EP2231024A4 (en) * | 2007-12-14 | 2015-03-18 | Ekos Corp | Ultrasound pulse shaping |
EP2231279A1 (en) * | 2007-12-28 | 2010-09-29 | Celleration, Inc. | Methods for treating inflammatory skin disorders |
DE102008038309A1 (en) * | 2008-08-19 | 2010-02-25 | Theuer, Axel E., Prof. Dr.-Ing. habil. | Device for destruction of tumor cells or pathogens in the bloodstream |
US20100106063A1 (en) * | 2008-10-29 | 2010-04-29 | Cabochon Aesthetics, Inc. | Ultrasound Enhancing Target for Treating Subcutaneous Tissue |
US8167280B2 (en) * | 2009-03-23 | 2012-05-01 | Cabochon Aesthetics, Inc. | Bubble generator having disposable bubble cartridges |
US20100256596A1 (en) * | 2009-04-07 | 2010-10-07 | Cabochon Aesthetics, Inc. | Fiber growth promoting implants for reducing the appearance of cellulite |
EP2448636B1 (en) * | 2009-07-03 | 2014-06-18 | Ekos Corporation | Power parameters for ultrasonic catheter |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
US9375223B2 (en) | 2009-10-06 | 2016-06-28 | Cardioprolific Inc. | Methods and devices for endovascular therapy |
US8740835B2 (en) * | 2010-02-17 | 2014-06-03 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
DE102010013703A1 (en) * | 2010-04-01 | 2012-12-27 | Oncowave Medical AG | Apparatus for diagnosis and therapy of malignant tumor in patient, has ultrasound unit connected to control unit, which is switched to therapy mode to determine tumor-specific frequencies and lethal intensity during sonication of tumor |
JP6291253B2 (en) | 2010-08-27 | 2018-03-14 | イーコス・コーポレイシヨン | Ultrasound catheter |
EP2654624B1 (en) | 2010-12-23 | 2023-10-04 | Twelve, Inc. | System for mitral valve repair and replacement |
US11458290B2 (en) | 2011-05-11 | 2022-10-04 | Ekos Corporation | Ultrasound system |
CA2840084C (en) | 2011-06-21 | 2019-11-05 | Foundry Newco Xii, Inc. | Prosthetic heart valve devices and associated systems and methods |
WO2013053099A1 (en) * | 2011-10-10 | 2013-04-18 | Liu Zheng | Use of microbubble combined with ultrasonic cavitation in liver trauma hemostasis |
US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
EA201400481A1 (en) | 2011-10-19 | 2014-10-30 | Твелв, Инк. | ARTIFICIAL HEART VALVE DEVICES, ARTIFICIAL MITRAL VALVES AND RELATED SYSTEMS AND METHODS |
US9039757B2 (en) | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
EA201400478A1 (en) | 2011-10-19 | 2014-10-30 | Твелв, Инк. | DEVICES, SYSTEMS AND METHODS OF PROTESIZING THE HEART VALVE |
US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
US20140128734A1 (en) | 2012-11-05 | 2014-05-08 | Ekos Corporation | Catheter systems and methods |
SG11201506154RA (en) | 2013-03-14 | 2015-09-29 | Ekos Corp | Method and apparatus for drug delivery to a target site |
US9101745B2 (en) | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
US10111747B2 (en) | 2013-05-20 | 2018-10-30 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
EP3074089A4 (en) | 2013-11-26 | 2017-07-26 | Alliqua Biomedical, Inc. | Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing |
US10092742B2 (en) | 2014-09-22 | 2018-10-09 | Ekos Corporation | Catheter system |
US10052394B2 (en) | 2014-11-21 | 2018-08-21 | General Electric Company | Microbubble tether for diagnostic and therapeutic applications |
CN107708581B (en) | 2015-06-10 | 2021-11-19 | Ekos公司 | Ultrasonic wave guide tube |
CN111658234B (en) | 2015-08-21 | 2023-03-10 | 托尔福公司 | Implantable heart valve devices, mitral valve repair devices, and associated systems and methods |
WO2017189276A1 (en) | 2016-04-29 | 2017-11-02 | Medtronic Vascular Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US558512A (en) * | 1896-04-21 | Strainer for coffee-pots | ||
US2961382A (en) * | 1957-07-25 | 1960-11-22 | Ortho Pharma Corp | Urokinase-a plasmiogen activator and methods of obtaining the same |
CA1083040A (en) * | 1976-02-09 | 1980-08-05 | Mostafa Fahim | Topical application of medication by ultrasound with coupling agent |
FR2445755A1 (en) | 1979-01-08 | 1980-08-01 | Harmand Pierre | TOOL HOLDER SPINDLE FOR PRECISION MACHINING |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4657756A (en) * | 1980-11-17 | 1987-04-14 | Schering Aktiengesellschaft | Microbubble precursors and apparatus for their production and use |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
US4657543A (en) * | 1984-07-23 | 1987-04-14 | Massachusetts Institute Of Technology | Ultrasonically modulated polymeric devices for delivering compositions |
US4762915A (en) * | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
US4750902A (en) * | 1985-08-28 | 1988-06-14 | Sonomed Technology, Inc. | Endoscopic ultrasonic aspirators |
US4797285A (en) * | 1985-12-06 | 1989-01-10 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Lipsome/anthraquinone drug composition and method |
EP0237051B1 (en) * | 1986-03-14 | 1991-05-02 | Fujisawa Pharmaceutical Co., Ltd. | Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same |
US4948587A (en) * | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
JPS63135179A (en) * | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
US5718921A (en) * | 1987-03-13 | 1998-02-17 | Massachusetts Institute Of Technology | Microspheres comprising polymer and drug dispersed there within |
US5040537A (en) * | 1987-11-24 | 1991-08-20 | Hitachi, Ltd. | Method and apparatus for the measurement and medical treatment using an ultrasonic wave |
DE3741201A1 (en) * | 1987-12-02 | 1989-06-15 | Schering Ag | ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT |
DE3741199A1 (en) * | 1987-12-02 | 1989-08-17 | Schering Ag | USE OF ULTRASONIC CONTRASTING AGENTS FOR ULTRASONIC LITHOTRIPSY |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
DE58908194D1 (en) * | 1988-02-05 | 1994-09-22 | Schering Ag | ULTRASONIC CONTRAST AGENTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS DIAGNOSTICS AND THERAPEUTICS. |
US4921478A (en) * | 1988-02-23 | 1990-05-01 | C. R. Bard, Inc. | Cerebral balloon angioplasty system |
US5158071A (en) | 1988-07-01 | 1992-10-27 | Hitachi, Ltd. | Ultrasonic apparatus for therapeutical use |
US4920954A (en) * | 1988-08-05 | 1990-05-01 | Sonic Needle Corporation | Ultrasonic device for applying cavitation forces |
JPH02180275A (en) * | 1988-12-29 | 1990-07-13 | Toshiro Tachibana | Medicine injection tool having ultrasonic wave oscillation element |
US4936281A (en) * | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
US5209720A (en) * | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5069664A (en) * | 1990-01-25 | 1991-12-03 | Inter Therapy, Inc. | Intravascular ultrasonic angioplasty probe |
EP0452516B1 (en) * | 1990-03-16 | 1995-09-27 | Siemens Aktiengesellschaft | Ultrasonic measuring head and method of use thereof |
US5216130A (en) * | 1990-05-17 | 1993-06-01 | Albany Medical College | Complex for in-vivo target localization |
US5197946A (en) | 1990-06-27 | 1993-03-30 | Shunro Tachibana | Injection instrument with ultrasonic oscillating element |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
CA2022019C (en) * | 1990-07-26 | 1992-12-29 | Michael Black | Catheter |
US5269291A (en) | 1990-12-10 | 1993-12-14 | Coraje, Inc. | Miniature ultrasonic transducer for plaque ablation |
US5997497A (en) | 1991-01-11 | 1999-12-07 | Advanced Cardiovascular Systems | Ultrasound catheter having integrated drug delivery system and methods of using same |
US5916192A (en) * | 1991-01-11 | 1999-06-29 | Advanced Cardiovascular Systems, Inc. | Ultrasonic angioplasty-atherectomy catheter and method of use |
DE69215722T3 (en) * | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
US5277913A (en) * | 1991-09-09 | 1994-01-11 | Thompson David H | Liposomal delivery system with photoactivatable triggered release |
DE69224911T2 (en) * | 1991-11-04 | 1998-12-03 | Baxter Int | ULTRASONIC DEVICE FOR ABLATION WITH CHANNEL FOR GUIDE WIRE |
JPH05262673A (en) * | 1992-03-19 | 1993-10-12 | Nippon Paint Co Ltd | Contrast medium for ultrasonic diagnosis |
US5380273A (en) * | 1992-05-19 | 1995-01-10 | Dubrul; Will R. | Vibrating catheter |
US5713848A (en) * | 1993-05-19 | 1998-02-03 | Dubrul; Will R. | Vibrating catheter |
US5261291A (en) * | 1992-08-17 | 1993-11-16 | Schoch Paul T | Ergonomic apparatus for controlling a vehicle |
US5362309A (en) * | 1992-09-14 | 1994-11-08 | Coraje, Inc. | Apparatus and method for enhanced intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis |
US5318014A (en) * | 1992-09-14 | 1994-06-07 | Coraje, Inc. | Ultrasonic ablation/dissolution transducer |
JP2746021B2 (en) * | 1992-10-20 | 1998-04-28 | 富士写真光機株式会社 | Ultrasonic probe |
US5630837A (en) * | 1993-07-01 | 1997-05-20 | Boston Scientific Corporation | Acoustic ablation |
JP3294387B2 (en) * | 1993-07-21 | 2002-06-24 | 立花 克郎 | Ultrasonic intensity distribution measurement method |
DE59409568D1 (en) * | 1993-09-09 | 2000-11-30 | Schering Ag | ACTIVE SUBSTANCES AND GAS CONTAINING MICROPARTICLES |
US5509896A (en) * | 1994-09-09 | 1996-04-23 | Coraje, Inc. | Enhancement of thrombolysis with external ultrasound |
US6210356B1 (en) * | 1998-08-05 | 2001-04-03 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US5628728A (en) * | 1995-05-31 | 1997-05-13 | Ekos Corporation | Medicine applying tool |
US5558092A (en) * | 1995-06-06 | 1996-09-24 | Imarx Pharmaceutical Corp. | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5707608A (en) * | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
US5735811A (en) * | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
WO1997029701A1 (en) * | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter based surgery |
US5836896A (en) * | 1996-08-19 | 1998-11-17 | Angiosonics | Method of inhibiting restenosis by applying ultrasonic energy |
US6024718A (en) * | 1996-09-04 | 2000-02-15 | The Regents Of The University Of California | Intraluminal directed ultrasound delivery device |
US5817048A (en) * | 1997-03-20 | 1998-10-06 | Brown University Research Foundation | Ultrasonic alternative to laser-based photodynamic therapy |
WO1998048711A1 (en) * | 1997-05-01 | 1998-11-05 | Ekos Corporation | Ultrasound catheter |
US6582392B1 (en) * | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6723063B1 (en) * | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
US6676626B1 (en) * | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6228046B1 (en) * | 1997-06-02 | 2001-05-08 | Pharmasonics, Inc. | Catheters comprising a plurality of oscillators and methods for their use |
JP4441000B2 (en) * | 1997-06-23 | 2010-03-24 | 克郎 立花 | Biological tissue processing device |
US20010053384A1 (en) * | 1997-07-07 | 2001-12-20 | James F. Greenleaf | Site-directed transfection with ultrasound and cavitation nuclei |
US6548047B1 (en) * | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6113558A (en) * | 1997-09-29 | 2000-09-05 | Angiosonics Inc. | Pulsed mode lysis method |
US6007514A (en) * | 1997-09-30 | 1999-12-28 | Nita; Henry | Ultrasound system with pathfinding guidewire |
US6896659B2 (en) * | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
US6508816B2 (en) * | 1998-03-27 | 2003-01-21 | John H. Shadduck | Medical instrument working end creating very high pressure gradients |
US6475183B1 (en) * | 1998-06-03 | 2002-11-05 | Baxter International Inc. | Direct dual filling device for sealing agents |
US6135976A (en) * | 1998-09-25 | 2000-10-24 | Ekos Corporation | Method, device and kit for performing gene therapy |
US6296619B1 (en) * | 1998-12-30 | 2001-10-02 | Pharmasonics, Inc. | Therapeutic ultrasonic catheter for delivering a uniform energy dose |
US6524251B2 (en) * | 1999-10-05 | 2003-02-25 | Omnisonics Medical Technologies, Inc. | Ultrasonic device for tissue ablation and sheath for use therewith |
US20020041898A1 (en) * | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
US20040019318A1 (en) * | 2001-11-07 | 2004-01-29 | Wilson Richard R. | Ultrasound assembly for use with a catheter |
DE60213457T2 (en) * | 2001-12-03 | 2007-10-18 | Ekos Corp., Bothell | ULTRASONIC CATHETER FOR SMALL VESSELS |
ATE520362T1 (en) * | 2001-12-03 | 2011-09-15 | Ekos Corp | CATHETER WITH MULTIPLE ULTRASONIC EMITTING PARTS |
AU2003212481A1 (en) * | 2002-02-28 | 2003-09-09 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US7207989B2 (en) * | 2003-10-27 | 2007-04-24 | Biosense Webster, Inc. | Method for ablating with needle electrode |
US7341569B2 (en) * | 2004-01-30 | 2008-03-11 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
CA2604380A1 (en) * | 2005-04-12 | 2006-10-19 | Ekos Corporation | Ultrasound catheter with cavitation promoting surface |
US20070083120A1 (en) * | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
-
1992
- 1992-03-19 DE DE69215722T patent/DE69215722T3/en not_active Expired - Fee Related
- 1992-03-19 EP EP92104789A patent/EP0504881B2/en not_active Expired - Lifetime
- 1992-03-19 CA CA002063529A patent/CA2063529A1/en not_active Abandoned
- 1992-03-19 AT AT92104789T patent/ATE146073T1/en active
- 1992-03-19 EP EP96108580A patent/EP0732106A3/en not_active Withdrawn
- 1992-03-20 US US07/855,545 patent/US5315998A/en not_active Ceased
-
1996
- 1996-05-30 US US08/652,690 patent/USRE36939E/en not_active Expired - Lifetime
-
1999
- 1999-08-16 US US09/375,339 patent/US6585678B1/en not_active Expired - Fee Related
-
2003
- 2003-03-26 US US10/400,337 patent/US20030191446A1/en not_active Abandoned
-
2008
- 2008-07-14 US US12/172,686 patent/US20080274097A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0732106A3 (en) | 2003-04-09 |
US6585678B1 (en) | 2003-07-01 |
EP0504881A2 (en) | 1992-09-23 |
US5315998A (en) | 1994-05-31 |
EP0504881B1 (en) | 1996-12-11 |
DE69215722T3 (en) | 2001-03-08 |
US20030191446A1 (en) | 2003-10-09 |
USRE36939E (en) | 2000-10-31 |
EP0504881B2 (en) | 2000-11-08 |
DE69215722D1 (en) | 1997-01-23 |
DE69215722T2 (en) | 1997-05-07 |
ATE146073T1 (en) | 1996-12-15 |
EP0732106A2 (en) | 1996-09-18 |
US20080274097A1 (en) | 2008-11-06 |
EP0504881A3 (en) | 1993-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE36939E (en) | Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same | |
Lauer et al. | Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis. | |
JP2710281B2 (en) | Ultrasound enhancement of transdermal drug delivery. | |
JP3176600B2 (en) | Magnetically responsive compositions for delivering bioactive substances | |
US5800392A (en) | Microporous catheter | |
US5509896A (en) | Enhancement of thrombolysis with external ultrasound | |
EP0639067B1 (en) | Use of perfluorcarbons for the preparation of potentiators of the ultrasound induced hyperthermia treatment of biological tissues | |
Joshi et al. | Sonicated transdermal drug transport | |
CA2081896A1 (en) | Drug delivery apparatus and method | |
US20040229830A1 (en) | Delivery of therapeutic compositions using ultrasound | |
AU5359194A (en) | Ultrasonic transdermal drug delivery system | |
JP2005504756A (en) | Injectable foam formulations and novel pharmaceutical applications | |
ATE135236T1 (en) | CONJUGATES TO INCREASE THE PERMEABILITY OF THE VESSELS | |
KR20070095937A (en) | A high-intensity focused ultrasound adjuvant and the screening method thereof | |
US20070183976A1 (en) | Composition for ultrasound therapy and pharmaceutical liquid composition containing the same | |
JP3614445B2 (en) | Composition for promoting ultrasound therapy and drug for promoting ultrasound therapy | |
Wible Jr et al. | Inhaled gases affect the ultrasound contrast produced by albunex® in anesthetized dogs | |
CN109529033A (en) | A kind of stable oxygen carrier microvesicle and its preparation method and application | |
Song et al. | Increase in tumor blood flow by pentoxifylline | |
JP3462561B2 (en) | Drug administration device | |
JPH0588687B2 (en) | ||
EP0831776A2 (en) | Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir | |
CN100333715C (en) | Magnetic medicinal microball for directional breaking nerve back root and its preparing method | |
Kost et al. | Phonophoresis | |
HASEGAWA et al. | 0 Manipulation of Tumor Oxygen and Physiology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |